# Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

Source: https://onco.cc/trials/nct07004413/  
OnCo record `nct07004413` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Charite University, Berlin, Germany, not yet recruiting.

## Summary

Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients is a phase 3, randomised interventional study registered as NCT07004413 by Charite University, Berlin, Germany, with a registry enrolment figure of 267 participants, started 2026-10-01 and due to reach its primary completion in 2028-10-01. Interventions recorded: FOLFIRI+cetuximab; Guardant360 ctDNA assay. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression-free survival (PFS) on treatment rate at 12 months. Colorectal eligibility wording from the registry: "Histologically confirmed, UICC stage IV unresectable adenocarcinoma of the colon or rectum". Sites: Germany. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: FIRE-11
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07004413
- Phase: 3
- Setting: Randomized Study to Compare First-line Treatment With Either Continuous or Intermittent Cetuximab Plus FOLFIRI in Patients With RAS/BRAF-wild-type Metastatic Colorectal Cancer (mCRC): AIO-KRK-0524 / FIRE-11
- Sponsor: Charite University, Berlin, Germany
- Enrolled: 267

## Sources

- ClinicalTrials.gov NCT07004413: https://clinicaltrials.gov/study/NCT07004413

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- companies: [Guardant Health](https://onco.cc/companies/guardant-health/), [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07004413.json